TB-500: what the research shows, open questions and how it differs from thymosin

What is TB-500?

TB-500 is a synthetic peptide marketed for recovery and for healing injuries. It is usually described as an actin-binding fragment of the natural protein thymosin beta-4: a short piece of it, not the full protein of 43 amino acids. Labeling in the unregulated market is inconsistent, though. Products sold as “TB-500” may also contain the full-length protein or other fragments. It is not an approved medicine. Source

How is it supposed to work?

TB-500 is credited with effects similar to those of full-length thymosin beta-4:

• Binding to actin, a component of the cell’s internal scaffolding.

• Promoting cell migration.

• Promoting the growth of new blood vessels.

• Dampening inflammatory responses.

A review of the regenerative biology of the full-length protein 1 also describes the mobilization of stem and progenitor cells and reduced scarring in models of skin, eye, heart and brain repair. These assumptions about the fragment rest mostly on carrying over animal data from the full-length protein. The fragment itself has been studied far less. The proposed mechanism and any possible benefit in humans are therefore separate questions.

Is it FDA-approved?

No. TB-500 has no FDA approval. On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding TB-500 as the free base and acetate for wound healing to the 503A list for compounding 2. The vote did not itself authorize compounding. On October 30, 2026, HHS announced a draft, nonbinding enforcement-discretion policy for certain single-ingredient products under specified conditions. Appendix B covers TB-500 acetate for subcutaneous or intramuscular use; this is not FDA approval or inclusion on the final bulk list. The report on the meeting names TB-500 among the peptides voted on, but not full-length thymosin beta-4. In sport, it is treated the same way as thymosin beta-4 and is prohibited at all times under the WADA list. HHS policy Federal Register notice

What does the research show?

Human data on the fragment are largely missing. There are no completed human efficacy studies of the TB-500 fragment, and no specific human safety data have been published. The clinical data concern full-length thymosin beta-4. That protein has been tested in small early trials, including a randomized dose-escalation study of safety and tolerability in venous leg ulcers 3. There is also a phase III trial of eye drops in neurotrophic keratopathy 4. These results cannot be applied directly to the fragment. The advertised regenerative benefit remains unresolved in humans.

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a synthetic fragment with the sequence Ac-LKKTETQ, which covers the actin-binding domain of thymosin beta-4. The natural full-length protein consists of 43 amino acids. The two molecules have different chemical identities and different regulatory histories. Clinical trials on corneal healing and venous ulcers used full-length thymosin beta-4, not the TB-500 fragment. The fragment contained in TB-500 was identified and characterized in 2012 in Drug Testing and Analysis 6.

Is TB-500 FDA-approved?

No. TB-500 is not FDA-approved. Removal from Category 2 after withdrawal of its nomination did not itself establish approval or compounding eligibility. The October 2026 HHS policy now describes a separate conditional enforcement-discretion approach for single-ingredient TB-500 acetate given subcutaneously or intramuscularly. The Federal Register describes this as a draft, nonbinding policy while final bulk-list rulemaking continues. It is not FDA approval or blanket permission for any TB-500 product. Source HHS policy Federal Register notice

Is TB-500 legal in the US?

A blanket claim that every pharmacy route is unavailable is no longer an adequate account of the US position. The October 2026 HHS policy describes conditional enforcement discretion for patient-specific, single-ingredient TB-500 acetate preparations for subcutaneous or intramuscular use. The compounder must satisfy the policy conditions; this does not validate an unregulated seller or guarantee a product’s quality. It also does not change anti-doping rules: TB-500 remains prohibited at all times under section S2 of the 2026 WADA Prohibited List, covering peptide hormones, growth factors, related substances, and mimetics. HHS policy Federal Register notice

Can a doctor prescribe TB-500?

A clinician and pharmacist must assess the actual formulation and current federal and state rules. The October 2026 HHS policy describes conditional enforcement discretion for single-ingredient TB-500 acetate for subcutaneous or intramuscular use, with a patient-specific prescription. Conditions include verified identity, a qualifying manufacturer and certificate of analysis, testing, labeling, reporting of serious adverse events and quality problems, and other applicable requirements. The Federal Register calls it a draft, nonbinding policy: it does not create a guaranteed right to prescribe or supply a product, grant FDA approval, or cover multi-peptide blends. HHS policy Federal Register notice

How does TB-500 differ from BPC-157?

TB-500 and BPC-157 are different synthetic peptides with different amino acid sequences, proposed mechanisms of action and origins. TB-500 is derived from the actin-binding domain of natural thymosin beta-4. BPC-157 is derived from a protein found in human gastric juice. The FDA nomination history includes both as withdrawn. The October 2026 HHS policy separately addresses certain single-ingredient acetate preparations under conditions; it does not cover their combination. Neither substance is FDA-approved, and both remain on the WADA Prohibited List. Neither has completed human efficacy trials for musculoskeletal uses. No FDA-approved or clinically validated protocols exist for combining the two. HHS policy Federal Register notice

Can TB-500 be detected in a doping test?

Yes. TB-500 and fragments of thymosin beta-4 can be detected in biological samples. Methods for detecting TB-500 in horse urine and plasma 8 were published in 2012 in the Journal of Chromatography A. A 2024 study of a horse population in Drug Testing and Analysis 9 also described a strategy for detecting thymosin beta-4 misuse in racehorses. In addition, a doping control laboratory proposed a method for detecting the TB-500 fragment in plasma and urine 6.

Are there human studies of TB-500?

As of September 2026, no completed, peer-reviewed human efficacy trials of the synthetic TB-500 fragment had been published. The FDA had not identified any data on human exposure 7. Clinical data exist for full-length thymosin beta-4 in ophthalmology. They include a randomized controlled phase 3 trial in neurotrophic keratopathy 4, published in 2022 in the International Journal of Molecular Sciences: N = 18; for the primary healing endpoint at 4 weeks, the figures were 60% versus 12.5%, p = 0.0656. These data concern the full-length molecule as a topical eye treatment, not systemically administered TB-500.

Are peptides legal again after 2026?

Peptides do not all share one regulatory status. TB-500’s April 2026 removal from Category 2 followed withdrawal of its nomination; that procedural change was not approval. The July 23 advisory vote favoring inclusion on the bulk list was also nonbinding. The FDA nomination and final bulk lists must now be read alongside the October 30 HHS announcement. Its conditional enforcement-discretion policy concerns specified single-ingredient substances, including TB-500 acetate for subcutaneous or intramuscular use, subject to detailed safeguards. The Federal Register describes the policy as draft and nonbinding; final bulk-list rulemaking remains separate. Other peptides and routes may fall outside its scope. Check the current primary documents and applicable state requirements rather than treating either a favorable vote or an older list entry as the complete legal answer. Source Source Source Source HHS policy Federal Register notice

References provided in the source article

Sources: the human evidence for the related full-length protein is limited to small early trials (for example Guarnera et al., Annals of the New York Academy of Sciences, 2007, DOI: 10.1196/annals.1415.003 5 ), indexed on PubMed; reporting on the July 2026 FDA advisory committee vote 2 ; and the WADA Prohibited List.

Provenance and editorial review status

Adapted for Nutrient Desk from the source article. The claims and source attributions in the original text still require clinical review. This draft has not been cleared for indexing.